The GLP-1 Price Report: What Semaglutide and Tirzepatide Actually Cost in 2026

In July 2026, the Get Skinny desk compiled the cash-pay cost of the leading GLP-1 weight-loss medications across manufacturer programs, telehealth providers, and pharmacy discount tools. No category of medicine has a wider gap between its sticker price and the price patients actually pay, and that gap is shifting fast in 2026. Here is what the numbers say, and the change that is about to reprice the whole market.

Finding 1: the list price and the real price differ by roughly tenfold. The published list price of brand-name semaglutide runs about $998 to $1,350 a month, the number you would pay with no program at all. Almost nobody pays it. Through manufacturer direct-to-consumer programs, Wegovy self-pay is $149 a month for lower doses and $199 for the 4 mg dose, and Ozempic has run an introductory $199 a month for the first fills. The single most important cost decision is not which drug, but which program you enroll in.

Finding 2: tirzepatide costs more than semaglutide, and scales with dose. Zepbound, the tirzepatide brand, is priced by dose through direct programs: roughly $299 a month for 2.5 mg vials, $399 for 5 mg, and $499 for the highest dose. Because patients titrate upward over their first months, the price you start at understates the price you maintain at. Budgeting from the starter dose is how the monthly cost quietly doubles.

Finding 3: the cheapest option is being phased out. Compounded semaglutide, sold through telehealth at roughly $149 to $300 a month, has been the budget path for cash-pay patients. That path is closing: following the FDA's April 2026 action on the bulk-compounding list, compounded versions are being phased out, and they were never FDA approved to begin with. Anyone building a plan around compounded pricing should expect to move to a brand direct program, and should price that in now rather than later.

Finding 4: insurance rarely rescues a cosmetic user. Most insurers, including large carriers, cover GLP-1s for weight loss only with prior authorization, typically requiring a documented BMI at or above 35 and six or more months of lifestyle intervention first. Patients using these drugs for moderate or cosmetic weight loss usually do not clear that bar and pay cash. Assuming insurance will cover it is the most common budgeting mistake.

Finding 5: the honest number is annual, and ongoing. At the best current cash price of about $149 a month, a year of semaglutide is roughly $1,800; at the top Zepbound dose near $499 a month it is closer to $6,000. And GLP-1s are not a course with an endpoint: studies consistently show weight regain after stopping, so the realistic cost is a recurring annual one, not a one-time expense. A responsible plan weighs the yearly figure at the maintenance dose, not the first month at the starter dose.

The bottom line. For GLP-1 weight loss the drug matters less to your wallet than the program you buy it through, and the cheapest current path is disappearing. Compare the direct-to-consumer programs by your actual target dose, confirm whether your insurer will cover you before assuming it, and budget the annual maintenance cost rather than the introductory month. The list price is a fiction; the program price is the real one.

Methodology and sources. Cash prices compiled July 2026 from manufacturer direct-to-consumer programs and pharmacy discount data reported by the National Consumers League and GoodRx, plus telehealth compounded pricing. Prices and program terms change frequently and vary by dose and eligibility; figures reflect rates advertised as of July 2026. Informational only, not medical or pricing advice.